All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @lagosgirliesroom on TikTok ยท 47s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @lagosgirliesroom's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I'm about to expose Legos big girls.
  2. 0:02Yeah, I'm just keeping where they're getting their weight loss injections, but I'm about to expose it.
  3. 0:05If you've been wondering how people are dropping 7 to 10 kg in 30 days without killing themselves in the gym or starving,
  4. 0:11this is it.
  5. 0:12Not a Zen pick, not Munjaro, but the same compound to Zepatay.
  6. 0:16You can't be looking out of shape or obese and expect to see a man who has spent the company on you
  7. 0:19invest in looking good to get return on investment.
  8. 0:21Easy maths.
  9. 0:21And guess what, it's now available in Nigeria through Dokitami, supervised by a real MDC and verified doctor.
  10. 0:26No crazy workout, no crash diets.
  11. 0:29Just actual science working with your body.
  12. 0:31This is literally what a lot of people are quietly using to transform their bodies fast.
  13. 0:35I got light for you.
  14. 0:36Don't dawl.
  15. 0:37If you've been waiting for a sign, this is it.
  16. 0:39Send a message to Dokitami now and get started.
  17. 0:42You don't have to break the bank to look good.
  18. 0:44And follow Dokitami for more inside info.

@lagosgirliesroom's weight-loss injection claims, fact-checked

Lagos Girlies Room ๐Ÿ’…๐Ÿ’•๐Ÿคฉ

TikTok creator

32.0K viewsWatch on TikTok โ†’

Quick answer

The video promotes what appears to be compounded tirzepatide, a dual GIP/GLP-1 receptor agonist, through a Nigerian telehealth service called Dokitami. The creator cites weight loss of 7, 10 kg in 30 days, a figure not supported as a mean outcome in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), which reported approximately 20.9% body weight reduction over 72 weeks. No information is provided about clinical screening, dosing protocols, or monitoring, which are required for safe use of injectable peptide therapies.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @lagosgirliesroom's weight-loss injection claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@lagosgirliesroom's weight-loss injection claims, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@lagosgirliesroom's weight-loss injection claims, fact-checked" from Lagos Girlies Room ๐Ÿ’…๐Ÿ’•๐Ÿคฉ. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video promotes what appears to be compounded tirzepatide, a dual GIP/GLP-1 receptor agonist, through a Nigerian telehealth service called Dokitami.

The reason this review is not generic is the source wording and the canonical claim label "glp1 get your weight loss injection from dokitami weightloss." In this clip, the useful excerpt is: "I'm about to expose Legos big girls." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Early rapid weight loss on GLP-1/GIP agonists partly reflects water and glycogen loss, not equivalent fat reduction.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video promotes what appears to be compounded tirzepatide, a dual GIP/GLP-1 receptor agonist, through a Nigerian telehealth service called Dokitami.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video promotes what appears to be compounded tirzepatide, a dual GIP/GLP-1 receptor agonist, through a Nigerian telehealth service called Dokitami. The creator cites weight loss of 7, 10 kg in 30 days, a figure not supported as a mean outcome in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), which reported approximately 20.9% body weight reduction over 72 weeks. No information is provided about clinical screening, dosing protocols, or monitoring, which are required for safe use of injectable peptide therapies.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed mean weight loss of 20.9% on tirzepatide, but over 72 weeks, not 30 days.
  • Early rapid weight loss on GLP-1/GIP agonists partly reflects water and glycogen loss, not equivalent fat reduction.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed mean weight loss of 20.9% on tirzepatide, but over 72 weeks, not 30 days.
  • Early rapid weight loss on GLP-1/GIP agonists partly reflects water and glycogen loss, not equivalent fat reduction.
  • Compounded tirzepatide is not regulatory-equivalent to Zepbound or Mounjaro; the FDA has stated this explicitly and repeatedly.
  • GLP-1 and GIP agonists reduce appetite as their core mechanism, meaning users are still in a caloric deficit, just drug-induced rather than willpower-induced.
  • Lean mass loss is a documented risk with rapid weight loss on semaglutide and tirzepatide without adequate protein intake (Wilding et al., 2021, NEJM).
  • Safe use of injectable peptide therapies requires baseline medical screening, contraindication review, and ongoing monitoring, none of which are mentioned in this video.
  • Urgency-based sales language such as 'Don't dawl, send a message now' is a marketing technique, not a medical recommendation.

Our take ยท Written by FormBlends editorial team ยท Reviewed by FormBlends Medical Team ยท This is not a transcript. It is our independent review of the video above.

What did @lagosgirliesroom actually say?

The creator claims she is revealing where Lagos women are secretly getting "weight loss injections" that cause people to drop "7 to 10 kg in 30 days without killing themselves in the gym or starving." She identifies the product as "the same compound" as tirzepatide, available in Nigeria through a service called Dokitami, supervised by a verified doctor.

She also frames the weight loss as a financial strategy: "You can't be looking out of shape or obese and expect to see a man who has spent the company on you invest in looking good to get return on investment." That framing is worth naming directly because it ties body composition to relationship worth, which is a separate problem from the medical claims, but it shapes why someone might skip the safety questions entirely.

The pitch ends with urgency: "Don't dawl. If you've been waiting for a sign, this is it." That is a classic direct-response sales technique, not a medical consultation.

Does the science back this up?

Tirzepatide is a real drug with strong clinical evidence. The claim that it produces rapid weight loss is not invented. But the specific numbers and timeline deserve scrutiny, and the "no diet, no exercise" framing misrepresents what the trials actually showed.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants on the highest dose of tirzepatide lost an average of 20.9% of body weight over 72 weeks. That is roughly 18 months. The dramatic early losses seen in some individuals, sometimes 3, 5 kg in the first four weeks, are partly water weight and glycogen depletion, not pure fat loss. Losing 7, 10 kg of actual fat in 30 days on any GLP-1 or GIP/GLP-1 agonist is not a typical or expected outcome. It is not impossible in a heavier individual with fluid changes, but advertising it as a standard result is misleading.

The SURMOUNT trials also included lifestyle counseling. Participants were not eating freely. Presenting tirzepatide as a replacement for dietary change contradicts the study conditions that produced those results.

What did they get wrong (or right)?

Credit where it is due: tirzepatide does work as a weight management agent, and the existence of compounded versions in markets outside the US and EU is a real phenomenon. Calling it "the same compound" as a branded product is where things go wrong legally and clinically. Compounded tirzepatide is not the same as Zepbound or Mounjaro in terms of regulatory approval, manufacturing standards, or verified bioequivalence. The FDA has been explicit about this distinction.

The "7 to 10 kg in 30 days" claim lacks a cited source. No peer-reviewed trial reports that as an average outcome at four weeks. It may reflect outlier anecdotes or marketing copy.

The framing of "no crash diets" is also inaccurate. GLP-1 and GIP agonists work partly by reducing appetite and slowing gastric emptying, which means users naturally eat less. Calling that "no dieting" is technically misleading: the drug produces the caloric deficit that a diet would otherwise require. Users still need adequate protein and nutritional guidance to avoid muscle loss, as shown in Wilding et al., 2021, NEJM, where lean mass loss was a documented concern.

What should you actually know?

Tirzepatide is a legitimate, evidence-backed medication. If you are considering it, the access pathway matters as much as the molecule. The creator mentions a "real MDC and verified doctor" but provides no details about what that supervision involves, how dosing is determined, or what monitoring is required.

GLP-1 and GIP agonists carry real side effects including nausea, vomiting, pancreatitis risk, and potential thyroid concerns flagged in animal studies (though not confirmed in humans at therapeutic doses per the SURMOUNT safety data). Starting without baseline bloodwork or a proper medical history review is a risk, not a shortcut.

Compounded peptides also vary in quality. Without knowing the source, concentration, and sterility standards of what Dokitami is dispensing, there is no way to verify the product matches what it claims to be. That is not a reason to dismiss compounding categorically, but it is a reason to ask harder questions before injecting anything.

If you are in Nigeria and genuinely interested in GLP-1 therapy, seek a consultation with a licensed physician who can review your metabolic health, contraindications, and goals before any prescription is written.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Lagos Girlies Room ๐Ÿ’…๐Ÿ’•๐Ÿคฉ ยท TikTok creator

32.0K views on this video

GET YOUR WEIGHT-LOSS INJECTION FROM @Dokitami #weightloss

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) showed mean weight loss?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed mean weight loss of 20.9% on tirzepatide, but over 72 weeks, not 30 days.

What does the video say about early rapid weight loss on glp-1/gip agonists partly reflects water?

Early rapid weight loss on GLP-1/GIP agonists partly reflects water and glycogen loss, not equivalent fat reduction.

What does the video say about compounded tirzepatide?

Compounded tirzepatide is not regulatory-equivalent to Zepbound or Mounjaro; the FDA has stated this explicitly and repeatedly.

What does the video say about glp-1?

GLP-1 and GIP agonists reduce appetite as their core mechanism, meaning users are still in a caloric deficit, just drug-induced rather than willpower-induced.

What does the video say about lean mass loss?

Lean mass loss is a documented risk with rapid weight loss on semaglutide and tirzepatide without adequate protein intake (Wilding et al., 2021, NEJM).

What does the video say about safe use of injectable peptide therapies requires baseline medical screening,?

Safe use of injectable peptide therapies requires baseline medical screening, contraindication review, and ongoing monitoring, none of which are mentioned in this video.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Lagos Girlies Room ๐Ÿ’…๐Ÿ’•๐Ÿคฉ, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.